Russia’s Enteromix Cancer Vaccine Enters Human Trials

Russia has developed an experimental cancer treatment called EnteroMix. It was created at the National Medical Research Radiological Center and is being described as a therapeutic vaccine. Unlike traditional vaccines that prevent infection, EnteroMix is designed to fight existing cancers by using non-pathogenic viruses that can target tumors and stimulate the immune system to attack cancer cells.

Human trials officially began in June 2025 with a small group of patients. This marks the first phase of clinical research where scientists are primarily focused on safety and on studying how the treatment interacts with the body. The first type of cancer being targeted is colorectal cancer, which is one of the most common and deadly cancers worldwide. Researchers have also suggested that the vaccine may later be tested for other cancers such as melanoma and glioblastoma, but those studies are still in the future.

Russian health officials have publicly stated that if EnteroMix is approved for medical use, the government intends to provide it free of charge to patients. The projected production cost has been estimated at around three hundred thousand rubles per treatment course, but the state has promised to cover this expense so that patients will not pay.At this stage EnteroMix is still experimental. The trials that began in 2025 are only the first step and further phases with larger numbers of patients are required before any official approval or wide availability. The vaccine is real, the trials are happening, and the plan for state-funded access has been announced. Those are the confirmed facts.